NysnoBio Receives $2.5 Million Grant from the California Institute for Regenerative Medicine (CIRM)
The California Institute for Regenerative Medicine (CIRM) has invested more than $109 million in helping research for Parkinson’s disease progress from a basic or Discovery level through clinical trials. The most recent investment is a $2.5 million award to Jennifer Johnston, PhD, CEO of NysnoBio GT Neurology. CIRM funding will support our precision medicine approach to deliver a healthy version of the Parkin gene to Parkinson's patients whose disease is caused by Parkin mutations.
Says Dr. Johnston:
“NysnoBio is honored to be awarded this prestigious grant from CIRM, whose funding is critical to advance pioneering therapies to cure human disease. CIRM is a uniquely steadfast supporter of cell and gene therapies, removing roadblocks and creating efficiencies to ensure integration of new therapeutic modalities into the healthcare arsenal against human disease and suffering.”
Read the full article here.
Contact NysnoBio to get involved or learn more:
info@nysnobio.com
